StageZero Life Sciences Ltd.

The call did not provide full Q1 revenue, EPS, or adjusted EBITDA figures. Management did state that corrected Q4 2023 revenue was approximately $675,000, and said Q1 revenue declined because of staff illness and delayed patient processing. Gross margin was said to be 58% after cost reductions and lab reorganization. On guidance, management said Aristotle is the primary focus for 2024, with significant revenue potential from the partnerships already in place, and that the company expects the backlog to convert as operations normalize. The company also said it is working to file the delayed 2023 year-end audited financials before the July 3 deadline referenced on the call.

James Howard Tripp framed the quarter as operationally disrupted but strategically productive. He said Aristotle is now the company's main thrust for the year, with several partnerships in place that he believes can drive meaningful revenue, including U.S. lab coverage, a western clinic group, and a Canadian executive health group. His tone was optimistic about the platform, emphasizing the company's integrated screening-to-treatment model, international expansion potential, and what he described as industry-leading science and improving algorithms.

No CFO spoke on the call; the CEO covered financial and operating commentary. He said the company had to delay its 2023 year-end audited filing because it lacked the funds to fully pay auditors, and that it is working to rectify that before the July 3 deadline. He also said the Richmond lab was reorganized, surplus costs were removed, and gross margin improved to 58%.

There was no live analyst Q&A; management asked for written questions only. The main issues raised were the delayed 2023 audited filing, the corrected Q4 2023 revenue figure of about $675,000, and the Q1 revenue decline caused by staff illness. Management answered by saying the backlog is being worked through, new patient flow is continuing, and the company expects operations and revenue to normalize as the year progresses.